Granted Patent
B2
US 12,564,739 · App. 18/429,244 · Granted Mar 3, 2026
Engineered natural killer (NK) cells and compositions and methods thereof
Assignee:
INDAPTA THERAPEUTICS, INC.
C07K14/7051A61K35/17A61K40/15A61K40/42A61P35/00C07K14/70535C07K16/2887C12N5/0646C12N9/22C12N15/11C12N15/1138C07K2317/24C07K2317/732C07K2317/76C07K2319/30C12N2310/14C12N2310/20C12N2510/00C12N2800/80
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides engineered Natural Killer (NK) cells and methods of producing engineered NK cells. The engineered NK cells and compositions containing the engineered NK cells are useful for treating diseases such as cancer.
Claims (25)
1 . A method of treating a cancer comprising administering engineered NK cells to an individual in need thereof, wherein the engineered NK cells are derived from a primary cell obtained from a human subject or is derived from a clonal cell line, in which a gene encoding FcRγ chain is genetically disrupted to knockout FcRγ in the engineered cell, wherein the individual in need thereof has been administered an antibody that recognizes a tumor associated antigen, wherein the engineered NK cells with the genetic disruption of the gene encoding FcRγ increase antibody dependent cellular cytotoxicity (ADCC) via CD16 expressed on the surface of the engineered cells compared to NK cells that are not genetically engineered with the genetic disruption.
2 . The method of claim 1 , wherein the tumor associated antigen is CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD40, CD52, CD56, CD70, CD74, CD140, EpCAM, CEA, gpA33, mesothelin, α-fetoprotein, Mucin, PDGFR-alpha, TAG-72, CAIX, PSMA, folate-binding protein, scatter factor receptor kinase, a ganglioside, cytokerain, frizzled receptor, VEGF, VEGFR, Integrin αVβ3, integrin α5β1, EGFR, EGFL7, ERBB2 (HER2), ERBB3, fibronectin, HGF, HER3, LOXL2, MET, IGF1R, IGLF2, EPHA3, FR-alpha, phosphatidylserine, Syndecan 1, SLAMF7 (CD319), TRAILR1, TRAILR2, RANKL, FAP, vimentin or tenascin.
3 . The method of claim 1 , wherein the CD16 is a CD16 that comprises a CD16-activating mutation.
4 . The method of claim 1 , wherein the CD16 is a CD16 that comprises a mutation that results in a higher affinity of CD16 to IgG1.
5 . The method of claim 1 , wherein the CD16 is a CD16 that comprises a 158V mutation.
6 . The method of claim 1 , wherein the cancer is leukemia or lymphoma.
7 . The method of claim 1 , wherein the cancer comprises a solid tumor.
8 . The method of claim 1 , wherein the engineered cells are administered in an amount from or from about 10 5 to about 10 12 cells.
9 . The method of claim 1 , wherein the individual is a human.
10 . The method of claim 1 , wherein the engineered NK cell is derived from a primary cell obtained from a human subject.
11 . A method of treating a cancer comprising administering:
(1) engineered NK cells to an individual in need thereof, wherein the engineered NK cells are derived from a primary cell obtained from a human subject or is derived from a clonal cell line, in which a gene encoding FcRγ chain is genetically disrupted to knockout FcRγ in the engineered cell, wherein the genetic disruption of the gene encoding FcRγ increases antibody dependent cellular cytotoxicity (ADCC) via CD16 expressed on the surface of the engineered cell compared to a NK cell that is not genetically engineered with the genetic disruption; and
(2) an antibody that recognizes a tumor associated antigen.
12 . The method of claim 11 , wherein the tumor associated antigen is CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD40, CD52, CD56, CD70, CD74, CD140, EpCAM, CEA, gpA33, mesothelin, α-fetoprotein, Mucin, PDGFR-alpha, TAG-72, CAIX, PSMA, folate-binding protein, scatter factor receptor kinase, a ganglioside, cytokerain, frizzled receptor, VEGF, VEGFR, Integrin αVβ3, integrin α5β1, EGFR, EGFL7, ERBB2 (HER2), ERBB3, fibronectin, HGF, HER3, LOXL2, MET, IGF1R, IGLF2, EPHA3, FR-alpha, phosphatidylserine, Syndecan 1, SLAMF7 (CD319), TRAILR1, TRAILR2, RANKL, FAP, vimentin or tenascin.
13 . The method of claim 11 , wherein the CD16 is a CD16 that comprises a CD16-activating mutation.
14 . The method of claim 11 , wherein the CD16 is a CD16 that comprises a mutation that results in a higher affinity of CD16 to IgG1.
15 . The method of claim 11 , wherein the CD16 is a CD16 that comprises a 158V mutation.
16 . The method of claim 11 , wherein the cancer is leukemia or lymphoma.
17 . The method of claim 11 , wherein the cancer comprises a solid tumor.
18 . The method of claim 11 , wherein the engineered cells are administered in an amount from or from about 10 5 to about 10 12 cells.
19 . The method of claim 11 , wherein the individual is a human.
20 . The method of claim 11 , wherein the engineered NK cell is derived from a primary cell obtained from a human subject.
21 . The method of claim 11 , wherein the antibody is administered before, after, or substantially simultaneously with the engineered NK cells.
22 . The method of claim 11 , wherein the individual in need thereof is administered about 0.1 mg/kg to about 100 mg/kg of the antibody.
23 . The method of claim 1 , wherein the individual in need thereof has been administered about 0.1 mg/kg to about 100 mg/kg of the antibody.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 3, 2025
From: DIPIERRO, GUY
To: INDAPTA THERAPEUTICS, INC.
Reel/Frame 072465/0799 →
Continuity (4)
Division
16484813
Provisional Application
62484350
· Apr 11, 2017
Provisional Application
62457098
· Feb 9, 2017
References Cited (324)
US 4683195A
· Mullis et al.
· 1987
[cited by applicant]
US 4683202A
· Mullis
· 1987
[cited by applicant]
US 4889818A
· Gelfand et al.
· 1989
[cited by applicant]
US 5350674A
· Boenisch et al.
· 1994
[cited by applicant]
US 5585362A
· Wilson et al.
· 1996
[cited by applicant]
US 5641870A
· Rinderknecht et al.
· 1997
[cited by applicant]
US 5716613A
· Guber et al.
· 1998
[cited by applicant]
US 5716826A
· Gruber et al.
· 1998
[cited by applicant]
US 5851529A
· Guber et al.
· 1998
[cited by applicant]
US 6168991B1
· Choi et al.
· 2001
[cited by applicant]
US 6428968B1
· Molnar-Kimber et al.
· 2002
[cited by applicant]
US 6506559B1
· Fire et al.
· 2003
[cited by applicant]
US 6632670B1
· Wadsworth et al.
· 2003
[cited by applicant]
US 6635472B1
· Lauermann
· 2003
[cited by applicant]
US 6653103B2
· Petersen et al.
· 2003
[cited by applicant]
US 6689871B1
· Wolfe et al.
· 2004
[cited by applicant]
US 6723316B2
· Laquerre et al.
· 2004
[cited by applicant]
US 6897045B2
· Engelhardt et al.
· 2005
[cited by applicant]
US 7001765B2
· Maass et al.
· 2006
[cited by applicant]
US 7033826B2
· Perricaudet et al.
· 2006
[cited by applicant]
US 7153510B1
· Rose
· 2006
[cited by applicant]
US 7172893B2
· Rabinowitz et al.
· 2007
[cited by applicant]
US 7238526B2
· Wilson et al.
· 2007
[cited by applicant]
US 7241447B1
· Engelhardt et al.
· 2007
[cited by applicant]
US 7537924B2
· Coffin
· 2009
[cited by applicant]
US 7550296B2
· Hermiston et al.
· 2009
[cited by applicant]
US 7588767B2
· Szalay et al.
· 2009
[cited by applicant]
US 7588771B2
· Szalay et al.
· 2009
[cited by applicant]
US 7662398B2
· Szalay et al.
· 2010
[cited by applicant]
US 7662627B2
· Johnson et al.
· 2010
[cited by applicant]
US 7731952B2
· Mohr et al.
· 2010
[cited by applicant]
US 7731974B2
· Bell et al.
· 2010
[cited by applicant]
US 7754221B2
· Szalay et al.
· 2010
[cited by applicant]
US 7811814B2
· Bohn et al.
· 2010
[cited by applicant]
US 7897146B2
· Brown et al.
· 2011
[cited by applicant]
US 7906111B2
· Wilson et al.
· 2011
[cited by applicant]
US 7927585B2
· Snyder
· 2011
[cited by applicant]
US 7943374B2
· Hildinger
· 2011
[cited by applicant]
US 7968340B2
· Hallek et al.
· 2011
[cited by applicant]
US 8007780B2
· Arbetman
· 2011
[cited by applicant]
US 20040009604A1
· Zhang et al.
· 2004
[cited by applicant]
US 20040063094A1
· Coffin et al.
· 2004
[cited by applicant]
US 20050220818A1
· Lorence
· 2005
[cited by applicant]
US 20050260601A1
· Whitt
· 2005
[cited by applicant]
US 20070110720A1
· Brown et al.
· 2007
[cited by applicant]
US 20070202572A1
· Szalay et al.
· 2007
[cited by applicant]
US 20080247990A1
· Campbell
· 2008
[cited by applicant]
US 20090098529A1
· Chen et al.
· 2009
[cited by applicant]
US 20090117034A1
· Chen et al.
· 2009
[cited by applicant]
US 20090136917A1
· Szalay et al.
· 2009
[cited by applicant]
US 20090162288A1
· Chen et al.
· 2009
[cited by applicant]
US 20100113567A1
· Barber
· 2010
[cited by applicant]
US 20100178684A1
· Woo et al.
· 2010
[cited by applicant]
US 20100196325A1
· Szalay et al.
· 2010
[cited by applicant]
US 20110064650A1
· Szalay
· 2011
[cited by applicant]
US 20110158948A1
· Brown et al.
· 2011
[cited by applicant]
US 20140086890A1
· Childs et al.
· 2014
[cited by applicant]
US 20170137784A1
· Masuyama
· 2017
[cited by applicant]
EP 1520175B1
· 2007
[cited by applicant]
EP 1606411B1
· 2008
[cited by applicant]
EP 1385466B1
· 2011
[cited by applicant]
EP 3539553
· 2019
[cited by applicant]
JP 2002504357A
· 2002
[cited by applicant]
JP 2011529341
· 2011
[cited by applicant]
JP 2012521215A
· 2012
[cited by applicant]
JP 2019170176
· 2019
[cited by applicant]
WO WO1999038955A2
· 1999
[cited by applicant]
WO WO1999043208A1
· 1999
[cited by applicant]
WO WO2005118854A1
· 2005
[cited by applicant]
WO WO2007052029A1
· 2007
[cited by applicant]
WO WO2010110734A1
· 2010
[cited by applicant]
WO WO2012061814A1
· 2012
[cited by applicant]
WO WO2009041113A1
· 2013
[cited by applicant]
WO WO2014145252A2
· 2014
[cited by applicant]
WO WO2016011210
· 2016
[cited by applicant]
WO WO2016011210A2
· 2016
[cited by examiner]
WO WO2016077734
· 2016
[cited by applicant]
WO WO2016077734A2
· 2016
[cited by examiner]
WO WO2016151741
· 2016
[cited by applicant]
WO WO2016201300A1
· 2016
[cited by applicant]
WO WO2017017184A1
· 2017
[cited by applicant]
WO WO2017048809
· 2017
[cited by applicant]
WO WO2017078807
· 2017
[cited by applicant]
WO WO2017079673
· 2017
[cited by applicant]
WO WO2017127729
· 2017
[cited by applicant]
WO WO2017127755
· 2017
[cited by applicant]
WO WO2018148462
· 2018
[cited by applicant]
WO WO2019222293
· 2019
[cited by applicant]
WO WO2020107002
· 2020
[cited by applicant]
WO WO2020135870A1
· 2020
[cited by applicant]
WO WO2020247392A1
· 2020
[cited by applicant]
Kucuksezer, Umut Can, et al. “The role of natural killer cells in autoimmune diseases.” Frontiers in immunology 12 (2021): 622306 (Year: 2021).
[cited by examiner]
Qian, Siyi et al. “Advancements in the Study of the Immune Molecule NKp46 in Immune System-related Diseases.” Clinical reviews in allergy & immunology vol. 67,1-3 (2024): 96-110. doi:10.1007/s12016-024-09010-5 (Year: 20…
[cited by examiner]
Romee, Rizwan et al. “NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17).” Blood vol. 121, 18 (2013): 3599-608. doi:10.1182/blood-2012-04-425397 (Year: 2013).
[cited by examiner]
Binyamin, Liat et al. Journal of immunology (Baltimore, Md.: 1950) vol. 180,9 (2008): 6392-401. doi: 10.4049/jimmunol.180.9.6392 (Year: 2008).
[cited by examiner]
Liu, Weiru et al. “FcRγ Gene Editing Reprograms Conventional NK Cells to Display Key Features of Adaptive Human NK Cells.” iScience vol. 23,11 101709. Oct. 20, 2020, doi:10.1016/j.isci.2020.101709 (Year: 2020).
[cited by examiner]
Fiegler, Nathalie, et al. “Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.” Blood, the Journal of the American Society of Hematology 122.5 (2013): 684-6…
[cited by examiner]
Adams et al., “Ambiguous allele combinations in HLA Class and Class II sequence-based typing: when precise nucleotide sequencing leads to imprecise allele identification,” J Transl Med. (2004) 2(1): 30.
[cited by applicant]
Alici et al. “Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components,” Blood, (2008). 111(6):3155-62.
[cited by applicant]
Alici et al. “Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model,” Exp Hematol, (2007). 35(12): 1839-1846.
[cited by applicant]
Allen et al., “Retargeted oncolytic measles strains entering via the EGFRIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity,” Cancer Res. (2006) 66(24): 11840-50.
[cited by applicant]
Amersdorfer et al., “Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries,” Infect Immun. (1997) 65(9): 3743-52.
[cited by applicant]
Anfossi et al., “Human NK Cell Education by Inhibitory Receptors for MHC Class I,” Immunity, 25(2): 331-342 (2006).
[cited by applicant]
Bachanova et al., “NK cells in therapy of cancer,” Grit Rev Oncog, (2014). 19(1-2):133-141.
[cited by applicant]
Bae et al., “Extracellular matrix for a rechargeable cell delivery system,” J Control Release. (1998) 53(1-3): 249-58.
[cited by applicant]
Balasa et al., “Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.” Cancer Immunol Immunother, (2015). 64:61-73, 13 pages.
[cited by applicant]
Benecia et al., “HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer,” Mol Ther. (2005) 12(5): 789-802.
[cited by applicant]
Benson et al., “IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect,” Blood, (2011). 118(24):6387-6391.
[cited by applicant]
Beurdeley et al., “Compact designer TALENs for efficient genome engineering,” Nat Commun. (2013) 4:1762.
[cited by applicant]
Beziat et al., “CMV drives clonal expansion of NKG2C1NK cellsexpressing self-specific KIRs in chronic hepatitis patients,” Eur. J. Immunol. (2012) 42: 447-457.
[cited by applicant]
Bhat et al., “Enhancement of NK cell antitumor responses using an oncolytic parvovirus,” Int J Cancer. (2011) 128(4): 908-19.
[cited by applicant]
Bhat et al., “NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells,” BMC Cancer. (2013) 13:367.
[cited by applicant]
Bida et al., “2B4 utilizes IT AM-containing receptor complexes to initiate intracellular signaling and cytolvsis,” Molecular immunology, 48(9-10): 1149-1159 (2011), 23 pages.
[cited by applicant]
Bigley et al., “Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells,” Brain Behav Immun. (2014) 39:160-71.
[cited by applicant]
Bigley et al., “NK cell function is impaired during long-duration spaceflight,” J Appl Physiol. (2018) 126:842-853.
[cited by applicant]
Bigley et al., “Latent cytomegalovirus infection enhances anti-tumour cytotoxicity through accumulation of NKG2C+ NK cells in healthy humans,” Clin Exp Immunol. (2016) 185(2): 239-51.
[cited by applicant]
Bigley et al., “Cytomegalovirus: an unlikely ally in the fight against blood cancers?,” Clin Exp Immunol. (2018) 193(3): 265-274.
[cited by applicant]
Binyamin et al., “Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy,” J Immunol. (2008) 180(9): 6392-401.
[cited by applicant]
Bjorkstrom et al., “Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education,” Blood, 116(19):3853-3864 (2010).
[cited by applicant]
Boerner et al., “Production of Antigen-Specific Human Monoclonal Antibodies From in Vitro-Primed Human Splenocytes,” J Immunol (1991) 147 (1), 86-95 (Abstract only).
[cited by applicant]
Bottino et al., “NK cell activating receptors and tumor recognition in humans,” Curr Top Microbiol Immunol. (2006) 298: 175-82.
[cited by applicant]
Bouhadir et al., “Degradation of partially oxidized alginate and its potential application for tissue engineering,” Biotechnol Prog. (2001) 17(5): 945-50.
[cited by applicant]
Brandt et al., “The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans,” Journal of Experimental Medicine, 206(7): 1495-1503 (2009).
[cited by applicant]
Brunetta, et al., “Chronic HIV-1 viremia reverses NKG2A/NKG2C ratio on natural killer cells in patients with human cytomegalovirus co-infection,” AIDS, (2010) 24(1):27-34.
[cited by applicant]
Bryant et al., “The effects of scaffold thickness on tissue engineered cartilage in photocrosslinked poly(ethylene oxide) hydrogels,” Biomaterials. (2001) 22(6): 619-26.
[cited by applicant]
Bryceson et al., “Line of attack: NK cell specificity and integration of signals,” Curr Opin Immunol. (2008) 20(3): 344-52.
[cited by applicant]
Burns et al., “IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial,” Bone Marrow Transplant, (2003). 32(2):177-86.
[cited by applicant]
Caligiuri et al., “Human natural killer cells,” Blood. Aug. 1, 2008;112(3):461-469.
[cited by applicant]
Campbell et al., “Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations,” Immunology, 132(3): 315-325 (2011).
[cited by applicant]
Capuano et al., “Tumor-Targeting Anti-CD20 Antibodies Mediate In Vitro Expansion of Memory Natural Killer Cells: Impact of CD16 Affinity Ligation Conditions and In Vivo Priming,” Front Immunol. (2018) 9:1031.
[cited by applicant]
Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” Proc Natl Acad Sci U S A. (1992) 89(10): 4285-9.
[cited by applicant]
Carter, “Potent antibody therapeutics by design,” Nature Reviews Immunology, 6(5): 343-357 (2006).
[cited by applicant]
Cartron et al., “Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcRIIIa gene,” Blood. (2002) 99(3): 754-758.
[cited by applicant]
Castagna et al., “Re-discovering NK cell allo-reactivity in the; therapy of solid tumors,” J Immunotherapy Cancer, (2016). 4:54, 3 pages.
[cited by applicant]
Cha et al., “Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains,” Journal of Virology, 70: 78-83 (1996).
[cited by applicant]
Chan et al., “Antibody-dependent cell-mediated cytotoxicity overcomes NK cell-resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands,” Clin Cancer Res, (2012). 18(22):6296-630…
[cited by applicant]
Chen et al., “Antibody mapping to domains of botulinum neurotoxin serotype A in the complexed and uncomplexed forms,” Infect Immun. (1997) 65(5):1626-30.
[cited by applicant]
Chen et al., “Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model,” Oncol Lett, (2016). 12(3):1868-1876.
[cited by applicant]
Cherkasova et al., “Treatment of Ex Vivo Expanded NK Cells with Daratumumab F(ab')2 Fragments Protects Adoptively Transferred NK Cells from Daratumumab-Mediated Killing and Augments Daratumumab-Induced Antibody Dependen…
[cited by applicant]
Chevalier et al., “Homing endonucleases: structural and functional insight into the catalysts of intron/intein mobility,” Nucleic Acids Res. (2001) 29(18): 3757-74.
[cited by applicant]
Childs et al., “Bringing Natural Killer Cells to the Clinic: Ex Vivo Manipulation,” American Society of Hematology (2013) 2013:234-246.
[cited by applicant]
Chomczynski et al., “Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction,” Anal Biochem. (1987) 162(1):156-159.
[cited by applicant]
Cichocki et al., “CD56dimCD57
[cited by applicant]
Cichocki et al., “GSK 3 inhibition drives maturation of NK cells and enhances their antitumor activity,” Cancer Res. (2017) 77(20): 5664-5675.
[cited by applicant]
Cichocki et al., “The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer,” Curr Top Microbiol Immunol. (2016) 395: 225-243.
[cited by applicant]
Cooley et al., “First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia,” Blood Adv. (2019) 3(13):1970-1980.
[cited by applicant]
Cooper et al., “In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells,” Blood, 100: 3633-3638 (2002).
[cited by applicant]
Cooper et al., “Memory-like responses of natural killer cells,” Immunol. Rev., 235: 297-305 (2010), 14 pages.
[cited by applicant]
Costa-Garcia et al., “Antibody-Mediated Response of NKG2Cbright NK Cells against Human Cytomegalovirus,” J Immunol (2015) 194(6): 2715-2724.
[cited by applicant]
Dahlberg et al., “Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity,” Frontiers in Immunology, (2015) vol. 6 article 605; pp. 1-19.
[cited by applicant]
De Maria et al., “The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44),” European Journal of immun…
[cited by applicant]
Dempe et al., “Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment,” Cancer Immunol Immunother. (2012) 61(11): 2113-23.
[cited by applicant]
Dubois et al., “Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8
[cited by applicant]
Durai et al., “Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells,” Nucleic Acids Res. (2005) 33(18): 5978-90.
[cited by applicant]
Fate Therapeutics, “Programmed Cellular Immunotherapies: Natural Killer Cell Franchise Update,” Nov. 10, 2018, pp. 1-58.
[cited by applicant]
Fauriat et al., “Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction,” Blood, 109(1): 323-330 (2007).
[cited by applicant]
Fauriat et al., “Regulation of human NK-cell cytokine and chemokine production by target cell recognition,” Blood, 115(11):2167-2176 (2010).
[cited by applicant]
Finnern et al., “Human autoimmune anti-proteinase 3 scFv from a phage display library,” Clin Exp Immunol. (1997) 107(2): 269-81.
[cited by applicant]
Fire et al., “Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans,” Nature (1998) 391: 806-811.
[cited by applicant]
Fire, A., “RNA-triggered gene silencing,” Trends Genet. (1999) 15(9): 358-63.
[cited by applicant]
Fishwild et al. “High avidity human IgG monoclonal antibodies from novel strains of minilocus transgenic mice.” Antibody Engineering II. New Technology, Application & Commercialization (W. Hori, Ed.) (1997): 187-211.
[cited by applicant]
Fishwild et al., “Abstract 1800: Human IgG kappa antigen-specific high affinity monoclonal antibodies from transgenic mice,” FASEB Journal, 12(4):A309.
[cited by applicant]
Fishwild et al., “Abstract 753: Human IgG kappa antigen-specific high affinity monoclonal antibodies from transgenic mice,” J Allergy Clin Immunol, (1997), 1 page.
[cited by applicant]
Fishwild et al., “High-avidity human IgGK monoclonal antibodies from a novel strain of minilocus transgenic mice,” Nature Biotechnology (1996) 14:845-851.
[cited by applicant]
Foley et al., “Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C
[cited by applicant]
Fujii et al. “A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity (ADCC) employing NK or high affinity NK (haNK) cells in combination with cetuximab” J Neurosurg., (2018). 128(5):1419-1427.
[cited by applicant]
Fujisaki et al., “Expansion of highly cytotoxic human natural killer cells for cancer cell therapy,” Cancer Res, (2009). 69(9):4010-4017.
[cited by applicant]
Gappa et al., “The effect of zinc-crystallized glucagon-like peptide-1 on insulin secretion of macroencapsulated pancreatic islets,” Tissue Eng. (2001) 7(1): 35-44.
[cited by applicant]
Garcia et al., “Human T cell receptor-mediated recognition of HLA-E,” Eur J Immunol. (2002) 32(4): 936-44.
[cited by applicant]
Garcia-Aragoncillo et al., “Design of virotherapy for effective tumor treatment,” Curr Opin Mol Ther. (2010) 12(4): 403-11.
[cited by applicant]
GenBank: ABQ28690.1, “CD3zeta chain, partial [
[cited by applicant]
Gong et al., “Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells,” Leukemia. (1994) 8(4):652-8.
[cited by applicant]
Grayson et al., “Cutting Edge: Increased Expression of Bcl-2 in Antigen-Specific Memory CDS
[cited by applicant]
Gujar et al., “Oncolytic virus-initiated protective immunity against prostate cancer,” Mol Ther. (2011) 19(4): 797-804.
[cited by applicant]
Guma et al., “Imprint of human cytomegalovirus infection on the NK cell receptor repertoire,” Blood, 104: 3664-3671 (2004).
[cited by applicant]
Hallden et al., “Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets,” Expert Opin Ther Targets. (2012) 16(10): 945-58.
[cited by applicant]
Hatjiharissi et al., “Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism,” Blood. (2007) 110(7…
[cited by applicant]
Heiber et al., “Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent,” J Virol. (2011) 85(20):10440-50.
[cited by applicant]
Hoogenboom et al., “Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains,” Nucleic Acids Res. (1991) 19(15):4133-4137.
[cited by applicant]
Hwang et al., “Identification of human NK cells that are deficient for signaling adaptor FcRα and specialized for antibody-dependent immune functions,” Int Immunol. (2012) 24(12): 793-802.
[cited by applicant]
Jamieson et al., “Turnover and Proliferation of NK Cells in Steady State and Lymphopenic Conditions,” The Journal of immunology, 172(2): 864-870 (2004).
[cited by applicant]
Jarahian et al., “Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase,” J Virol. (2009) 83(16): 8108-21.
[cited by applicant]
Jeong et al., “Thermogelling biodegradable copolymer aqueous solutions for injectable protein delivery and tissue engineering,” Biomacromolecules. (2002) 3(4):865-8.
[cited by applicant]
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature (1986) 321(6069):522-525.
[cited by applicant]
Kikuchi-Maki et al., “Cutting Edge: KIR2DL4 Transduces Signals into Human NK Cells through Association with the Fe Receptor y Protein,” The Journal of Immunology, 174(7): 3859-3863 (2005).
[cited by applicant]
Kim et al., “FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma,” Blood. (2006) 108(8) :2720-2725.
[cited by applicant]
Kim et al., “HLA alleles determine differences in human natural killer cell responsiveness and potency,” PNAS, 105(8): 3053-3058 (2008).
[cited by applicant]
Kim et al., “Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer,” Nat Rev Cancer. (2009) 9(1): 64-71.
[cited by applicant]
Klingemann et al., “Natural Killer Cells for Immunotherapy—Advantages of the NK-92 Cell Line over Blood NK Cells,” Frontiers in Immunology, (2016) vol. 7, article 91 pp. 1-7.
[cited by applicant]
Klingemann, H., “P33. NK-92 cellular immunotherapy as an alternative to donor derived peripheral blood NK cells,”, J Immunother Cancer (2014) 2(Suppl 2): P24.
[cited by applicant]
Koene et al., “FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype,” Blood. (1997) 90(3): 1109-1114.
[cited by applicant]
Kohrt et al., “CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies,” Blood, 117(8): 2423-2432 (2011).
[cited by applicant]
Kuijpers et al., “Human NK cells can control CMV infection in the absence of T cells,” Blood, 112: 914-915 (2008).
[cited by applicant]
Lahiji et al., “Chitosan supports the expression of extracellular matrix proteins in human osteoblasts and chondrocytes,” J Biomed Mater Res. (2000) 51(4): 586-95.
[cited by applicant]
Lanier, “Up on the tightrope: natural killer cell activation and inhibition,” Nat Immunol. (2008) 9(5): 495-502.
[cited by applicant]
Lee et al., “Epigenetic Modification and Antibody-Dependent Expansion of Memory-like NK Cells in Human Cytomegalovirus-Infected Individuals,” Immunity, (2015). 42:431-442, 20 pages.
[cited by applicant]
Lee et al., “Preparation of poly(vinyl alcohol)-chondroitin sulfate hydrogel as matrices in tissue engineering,” Carbohydrate Polymers. (2005) 61:348.
[cited by applicant]
Lee et al., “The effects of cross-linking of collagen-glycosaminoglycan scaffolds on compressive stiffness, chondrocyte-mediated contraction, proliferation and biosynthesis,” Biomaterials. (2001) 22(23): 3145-3154.
[cited by applicant]
Lee et al., “Formation of FcRγ-deficient NK cell subset associated with HCMV-reactivation in hematopoietic cell transplant recipients.” Journal of Clinical Oncology, (2017). 35(7):131, 3 pages.
[cited by applicant]
Lee et al., “HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences,” J Immunol., (1998). 160(10):4951-60.
[cited by applicant]
Lin et al., “Handbook of Practical Immunohistochemistry, Table of Contents,” 2nd Ed., Springer, 2015, 5 pages.
[cited by applicant]
Liu et al., “FcR gamma Gene Editing Reprograms Conventional NK Cells to Display Key Features of Adaptive Human NK Cells,” iScience, (2020). 23:101709, 10 pages.
[cited by applicant]
Lonberg et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications,” Nature (1994) 368(6474):856-859.
[cited by applicant]
Lonberg et al., “Human antibodies from transgenic mice,” Int Rev Immunol. (1995) 13(1): 65-93.
[cited by applicant]
Lopez-Verges et al., “CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16
[cited by applicant]
Lopez-Verges et al., “Expansion of a unique CD57
[cited by applicant]
Magri et al., “NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies,” Blood, 117: 848-856 (2011).
[cited by applicant]
Mak et al., “TAL effectors: function, structure, engineering and applications,” Curr Opin Struct Biol. (2013) 23(1): 93-9.
[cited by applicant]
Mali et al., “Cas9 as a versatile tool for engineering biology,” Nat. Methods (2013) 10(10): 957-963.
[cited by applicant]
Mann et al., “Smooth muscle cell growth in photopolymerized hydrogels with cell adhesive and proteolytically degradable domains: synthetic ECM analogs for tissue engineering,” Biomaterials. (2001) 22(22): 3045-51.
[cited by applicant]
Marks et al., “By-passing immunization. Human antibodies from V-gene libraries displayed on phage,” J Mol Bio (1991) 222(3):581-597.
[cited by applicant]
Marks et al.,“Molecular evolution of proteins on filamentous phage. Mimicking the strategy of the immune system,” J Biol Chem. (1992) 267(23): 16007-10.
[cited by applicant]
Mavilio et al., “Natural killer cells in HIV-1 infection: Dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates,” PNAS, 100(25): 15011-15016 (2003).
[cited by applicant]
McLoughlin et al., “TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up,” Ann Surg Oncol. (2005) 12…
[cited by applicant]
Mellor et al., “A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer,” J Hematol Oncol. (2013) 6:1, 10 pages.
[cited by applicant]
Miller et al., “Requirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma model,” Mol Ther. (2003) 7(6):741-7.
[cited by applicant]
Miltenyi Biotec Handbook (2022, pp. 1-7) (Year: 2022).
[cited by applicant]
Miyamoto et al., “Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma,” Cancer Res. (2012) 72(10): 2609-21.
[cited by applicant]
Mumtaz et al., “Design of liposomes for circumventing the reticuloendothelial cells,” Glycobiology. (1991) 1(5):505-510.
[cited by applicant]
Musolino et al., “Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer,” J Clin Oncol. (2008) 26(11): 1789-17…
[cited by applicant]
Nagashima et al., “Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo,” Blood. (1998) 91(10): 3850-3861.
[cited by applicant]
Narni-Mancinelli et al., “Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor,” PNAS, 108(45): 18324-18329 (2011).
[cited by applicant]
NCBI Reference Sequence: NP 001018091.1, “killer cell immunoglobulin-like receptor 2DL5B precursor [
[cited by applicant]
NCBI Reference Sequence: NP 001074239.1, “killer cell immunoglobulin-like receptor 2DL4 isoform c precursor [
[cited by applicant]
NCBI Reference Sequence: NP 001074241.1, “killer cell immunoglobulin-like receptor 2DL4 isoform b precursor [
[cited by applicant]
NCBI Reference Sequence: NP 001077008.1, “killer cell immunoglobulin-like receptor 3DS1 isoform 1 precursor [
[cited by applicant]
NCBI Reference Sequence: NP 001138938.1, “natural cytotoxicity triggering receptor 3 isoform b precursor [
[cited by applicant]
NCBI Reference Sequence: NP 001138939.1, “natural cytotoxicity triggering receptor 3 isoform c precursor [
[cited by applicant]
NCBI Reference Sequence: NP 001229796.1, “killer cell immunoglobulin-like receptor 3DL2 isoform 2 precursor [
[cited by applicant]
NCBI Reference Sequence: NP 002246.5, “killer cell immunoglobulin-like receptor 2DL4 isoform a precursor [
[cited by applicant]
NCBI Reference Sequence: NP 004097.1, “high affinity immunoglobulin epsilon receptor subunit gamma precursor [
[cited by applicant]
NCBI Reference Sequence: NP 004819.2, “natural cytotoxicity triggering receptor 2 isoform 1 precursor [
[cited by applicant]
NCBI Reference Sequence: NP 006728.2, “killer cell immunoglobulin-like receptor 3DL2 isoform 1 precursor [
[cited by applicant]
NCBI Reference Sequence: NP 014931.1, “Mpd1 p [
[cited by applicant]
NCBI Reference Sequence: NP 036444.1, “killer cell immunoglobulin-like receptor 2DS2 isoform a precursor [
[cited by applicant]
NCBI Reference Sequence: NP 036445.1, “killer cell immunoglobulin-like receptor 2DS3 precursor [
[cited by applicant]
NCBI Reference Sequence: NP 036446.3, “killer cell immunoglobulin-like receptor 2DS4 isoform 1 precursor [
[cited by applicant]
NCBI Reference Sequence: NP 037421.2, “killer cell immunoglobulin-like receptor 3DL 1 isoform 1 precursor [
[cited by applicant]
NCBI Reference Sequence: NP 055327.1, “killer cell immunoglobulin-like receptor 2DS1 precursor [
[cited by applicant]
NCBI Reference Sequence: NP 056952.2, “killer cell immunoglobulin-like receptor 2DL3 precursor [
[cited by applicant]
NCBI Reference Sequence: NP 065396.1, “killer cell immunoglobulin-like receptor 2DL5A precursor [
[cited by applicant]
NCBI Reference Sequence: NP 076036.1, “INO80 complex subunit B [Mus musculus],” retrieved online <https://ncbi.nlm.nih.gov/protein/NP_076036.1>, 2 pages (2019).
[cited by applicant]
Ogbomo et al., “Tumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cells,” Med Microbiol Immunol. (2010) 199(2): 93-101.
[cited by applicant]
O'Leary et al., “T cell- and B cell-independent adaptive immunity mediated by natural killer cells,” Nature immunology, 7: 507-516 (2006).
[cited by applicant]
Orange., “Formation and function of the lytic NK-cell immunological synapse,” Nature Reviews immunology, 8(9): 713-725 (2008), 26 pages.
[cited by applicant]
Parkhurst et al., “Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression,” Clin Cancer Res., (2011). 17(19):6287-97.
[cited by applicant]
Parsons et al., “Killer cell immunoglobulin-like receptor 3DL 1 licenses CD16-mediated effector functions of natural killer cells,” Journal of Leukocyte Biology, 88(5): 905-912 (2010).
[cited by applicant]
Paust et al., “Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen specific memory of haptens and viruses,” Nature immunology, 11: 1127-1135 (2010).
[cited by applicant]
Pende et al., “Identification and Molecular Characterization of Nkp30, a Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells,” Journal of Experimental Medicine, 190(10): 150…
[cited by applicant]
Presta, “Antibody engineering,” Curr Opin Biotechnol. (1992) 3(4):394-8.
[cited by applicant]
Ran et al., “Genome engineering using the CRISPR-Cas9 system,” Nat Protoc. (2013) 8(11): 2281-2308.
[cited by applicant]
Ranson et al., “IL-15 is an essential mediator of peripheral NK-cell homeostasis,” Blood, 101: 4887-4893 (2003).
[cited by applicant]
Ravetch et al. “IgG Fc Receptors,” Annu. Rev. Immunol. (2001) 19: 275-290.
[cited by applicant]
Reichmann et al. “Reshaping human antibodies for therapy,” Nature (1988) 332(6162):323-327.
[cited by applicant]
Reisfeld et al., “Monoclonal antibodies and cancer therapy,” available online at <https://www.osti.gov/biblio/6081141>, (1985), 2 pages. Abstract Only.
[cited by applicant]
Rintoul et al., “ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic,” Mol Ther. (2012) 20(6): 1148-57.
[cited by applicant]
Roda et al., “Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells,” Cancer Res. (2006) 66(1): 517-526.
[cited by applicant]
Saiki et al., “Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes,” Nature. (1986) 324(6093):163-6.
[cited by applicant]
Sallusto et al., “Two subsets of memory T lymphocytes with distinct homing potentials and effector functions,” Nature, 401 :708-712 (1999).
[cited by applicant]
Schlub et al., “Comparing the Kinetics of NK Cells, CD4, and CD8 T Cells in Murine Cytomegalovirus Infection,” The Journal of immunology, 187: 1385-1392 (2011).
[cited by applicant]
Schlums et al., “Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function,” Immunity. (2015) 42(3): 443-456.
[cited by applicant]
Shah et al., “Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity,” PLoS One. (2013) 8(10):e76781, 9 pages.
[cited by applicant]
Siegler et al., (2010). “Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients,” Cytother…
[cited by applicant]
Smidsrød et al., “Alginate as immobilization matrix for cells,” Trends Biotechnol. (1990) 8(3): 71-78.
[cited by applicant]
Smith, “HLA typing by direct DNA sequencing,” Methods Mol Biol. (2012) 882: 67-86.
[cited by applicant]
Somboonyosdech et al., “Correlation of FcγRIIIa polymorphisms and responses to rituximab in Thai population,” Asian Biomedicine (2012) 6(6):883-889.
[cited by applicant]
Stewart et al., “Strategies of natural killer cell recognition and signaling,” Curr Top Microbiol Immunol. (2006) 298: 1-21.
[cited by applicant]
Stoddard, “Homing endonuclease structure and function,” Q Rev Biophys. (2005) 38(1): 49-95.
[cited by applicant]
Suggs et al., “Development of poly(propylene fumarate-co-ethylene glycol) as an injectable carrier for endothelial cells,” Cell Transplant. (1999) 8(4):345-50.
[cited by applicant]
Suh et al., “Application of chitosan-based polysaccharide biomaterials in cartilage tissue engineering: a review,” Biomaterials. (2000) 21(24): 2589-98.
[cited by applicant]
Sun et al., “Adaptive immune features of natural killer cells,” Nature, 457: 557-561 (2009), 18 pages.
[cited by applicant]
Sutlu et al., “Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor.” Cytotherapy, (2010). 12(8):1044-55.
[cited by applicant]
Tai et al., “Attacking Postoperative Metastases using Perioperative Oncolytic Viruses and Viral Vaccines,” Front Oncol. (2014) 4: 217.
[cited by applicant]
Takai T et al. “FcR gamma chain deletion results in pleiotrophic effector cell defects.” Cell, (1994). 76(3):519-29, 12 pages.
[cited by applicant]
Tate et al., “Biocompatibility of methylcellulose-based constructs designed for intracerebral gelation following experimental traumatic brain injury,” Biomaterials. (2001) 22(10): 1113-23.
[cited by applicant]
Tomasec et al., “Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40,” Science. (2000) 287(5455): 1031.
[cited by applicant]
UniProtKB/Swiss-Pro Reference Sequencet: O95944.2, “RecName: Full=Natural cytotoxicity triggering receptor 2; AltName: Full=Lymphocyte antigen 95 homolog; AltName: Full=NK cell-activating receptor; AltName: Full=Natural…
[cited by applicant]
Verhoyen et al., “Reshaping human antibodies: grafting an antilysozyme activity,” Science (1998) 239(4847):1534-1536.
[cited by applicant]
Mvier et al., “Innate or Adaptive Immunity? The Example of Natural Killer Cells,” Science, 331 (6013): 44-49 (2011).
[cited by applicant]
White et al., “Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial,” Gene Ther. (2008) 15(12): 911-20.
[cited by applicant]
Yawata et al., “Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function,” Journal of Experimental Medicine, 203(3): 633-645 (2006).
[cited by applicant]
Yokoyama et al., “How Do Natural Killer Cells Find Self to Achieve Tolerance?,” Immunity, 24(3): 249-257 (2006).
[cited by applicant]
Yu et al., “Hierarchy of the Human Natural Killer Cell Response Is Determined by Class and Quantity of Inhibitory Receptors for Self-HLA-B and HLA-C Ligands,” The Journal of immunology, 179(9) :5977-5989 (2007).
[cited by applicant]
Zapata et al., “Engineering Linear F(ab')2 Fragments for Efficient Production in
[cited by applicant]
Zhang et al., “Antibody-dependent memory-like NK cells distinguished by FcRγ-deficiency,” J Immunol. (2013) 190(4): 1402-1406.
[cited by applicant]
Zhang et al., “Cutting edge: antibody-dependent memory-like NK cells distinguished by FcRγ deficiency,” J Immunol. 2013;190(4): 1402-6.
[cited by applicant]
Zhao et al., “A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity,” PLoS One. (2014) 9(3): e93103, 11 pages.
[cited by applicant]
Zhongguo et al. “Construction of pcDNA3.1(
[cited by applicant]
Biron et al., “Severe Herpesvirus Infections in an Adolescent without Natural Killer Cells,” The New England Journal of Medicine, 320: 1731-1735 (1989).
[cited by applicant]
Etzioni et al., “Fatal varicella associated with selective natural killer cell deficiency,” The Journal of Pediatrics, 146(3): 423-425 (2005).
[cited by applicant]
Lanier et al., “Co-association of CD3˜ with a receptor (CD16) for IgG Fe on human natural killer cells,” Nature, 342(6251): 803-805 (1989).
[cited by applicant]
Moretta et al., “Surface NK receptors and their ligands on tumor cells,” Seminars in Immunology, 18(3): 151-158 (2006).
[cited by applicant]
ATCC, “NK-92 MI, CRL 2402,” Available online at < https://www.atcc.org/products/crl-2408>, 4 pages (2022).
[cited by applicant]
Parham., “MHC class I molecules and kirs in human history, health and survival,” Nature Reviews immunology, 5(3): 201-214 (2005).
[cited by applicant]
Pernick, Handbook of Practical Immunohistochemistry, 2nd Ed., Springer, Table of Contents, 11 pages (2015).
[cited by applicant]
Petersen et al., “Short-term exposure to human cytomegalovirus-infected fibroblasts induces a proportional increase of active CD94/NKG2A
[cited by applicant]
Vivier et al., “Structural similarity between Fe receptors and T cell receptors. Expression of the gamma-subunit of Fe epsilon RI in human T cells, natural killer cells and thymocytes,” The Journal of immunology, 147(12…
[cited by applicant]
Bigley et al., “Abstract 1630: FceR1g negative NK-cells (g-NK) enhance antibody-dependent cellular cytotoxicity and in vivo efficacy of therapeutic monoclonal antibodies against hematologic malignancies,” Cancer Res (20…
[cited by applicant]
Bigley et al., (2021). “FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma,” Blood Advances, 5(15):3021-3031.
[cited by applicant]
CreativeBiolabs, (2021). “NK Cell Genetic Engineering Service,” available online at <http://web.archive.org/web/20210614110517/https://www.creative-biolabs.com/car-t/nk-cell-genetic-engineering.htm>, 8 pages.
[cited by applicant]
Imamura et al., (2014). “Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15,” Blood, 124(7):1081-8.
[cited by applicant]
Islam et al., (2021). “Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy,” Cells, 10(5):1058, 31 pages.
[cited by applicant]